INTRODUCTION

D iscovered by Henry Sherwood Lawrence in 1955,
the Transfer Factor (TF) is an extract obtained from calf splenic cells, consisting of a conjugated polypeptide with molecular weight around 6,000 Daltons and structure similar to the RNA [1] [2] [3] . TF has an important immune stimulatory function, promoting the maturation and differentiation of thymocytes in T lymphocytes, the restoration of function of malfunctioning peripheral lymphocytes, the recovery of humoral immunity through differentiation of B lymphocytes, forming plasmocytes and synthesizing specific humoral antibodies, the increase in allogeneic graft rejection capacity, the in vitro activation of T lymphocytes through cytotoxic action, lymphokine production and increased activity of the mononuclear phagocytic system. When administered orally, it establishes direct contact with the 
RESULTS
In the statistical analysis, all the samples evaluated had a normal distribution by the Kolmogorov and Smirnov (KS) method. The characteristics of the patients analyzed are contained in table 1. and 19%, respectively. Statistical analysis of these variations was very significant (Table 3) .
When we evaluated the means of the results in the studied period, we observed that in all of them there was an increase in values, which was more expressive after 12 months of treatment, as shown in figure 1 .
When analyzing the means of the leukocyte counts, we observed an increase of 5.6% when comparing the rates before treatment with those after six months, of 20.1% between pre-treatment and 12 months, and of 12.4% between six and 12 months of treatment.
Regarding total lymphocyte means, this increase was 5%, 24.8% and 14.9%, respectively. Statistical analysis of these variations was very significant (Table 2) . the schedules used to be interrupted, which compromises treatment results [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
The lymphocytes and their T subclasses are fundamental for the immune response, especially regarding solid tumors. Therefore, the combats to this type of tumor have the objective of making T-lymphocytes active and competent 16, 17, 19, 20 . In this study, we observed that the total lymphocytes and their subclasses showed an increase in counts, which was more pronounced with TF use for 12 months, and even when counts fell in the first six months of treatment, these were recovered after 12 months. The best response was evidenced by the subpopulation of CD4-lymphocytes, with an increase of 80% at the end of the study, and among those who had an initial decrease, 76% of presented an increase with 12 months
We also sought to analyze the effect of TF on total leukocytes, and we also observed an increase in counts in 83.3% of the cases with 12 months of therapy and, similar to lymphocytes, the 85.7% that had an initial reduction displayed higher rates after 12 months of TF use.
We conclude that TF promoted the activation of leukocytes, total lymphocytes and their subclasses, resulting in a stimulation of the immune response, specially when used for a period of 12 months.
Objetivo: avaliar a ação do Fator de Transferência na resposta imunológica de pacientes portadores de neoplasia maligna submetidos à cirurgia, quimioterapia e radioterapia. Método: análise das variações dos valores dos leucócitos, linfócitos totais, linfócitos T e CD4 em 60 pacientes submetidos à imunoestimulação com Fator de Transferência administrado em dose única de 0,5mg por via sublingual, diariamente e iniciada simultaneamente à quimioterapia e/ou radioterapia. 
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